This powerful antioxidant, is vital to the body, and is commonly depleted. This IV can help enhance energy, and protect your body from damaging oxidants. There is a lot of clinical data available utilizing IV glutathione for several conditions including chronic stress.
Glutathione is a molecule made up of three amino acids, and is considered by many as the “master antioxidant.” Antioxidants are important for reducing and eliminating reactive oxygen species (ROS), which cause a majority of the damage to the cells in your body. Several chronic conditions like cancer and heart disease have been linked to high levels of oxidative stress. Also, glutathione is helpful in detoxification but making chemicals easier to eliminate by conjugation. And, glutathione is used in the creation of energy in the citric acid cycle.1, 2
Several conditions may benefit from IV glutathione, like Parkinson’s disease and multiple sclerosis. Parkinson’s disease is a result of free radical and oxidative damage to the substantia nigra. The substantia nigra produces a movement molecule dopamine. Because glutathione protects against oxidative damage, researchers studied Parkinson’s patient’s glutathione levels and found that a majority of them were deficient.3 This led to further studies showing that IV glutathione significantly improves Parkinson’s symptoms.4
Another chronic neurodegenerative disease, multiple sclerosis, is a condition where the myelin sheaths around nerves degenerate. These sheaths help with nerve conduction. This damage is thought to be caused by oxidative and free radical damage. Studies have shown that patients with MS are low in glutathione as well. This would suggest that IV glutathione may be beneficial as well.5
- Jefferies H, Coster J, Khalil A, Bot J, McCauley RD, Hall JC. Glutathione.ANZ J Surg. 2003 Jul;73(7):517-22.
- Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases.Arch Physiol Biochem. 2007 Oct-Dec;113(4-5):234-58.
- Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia neigra of patients with Parkinson’s disease. Neurosci Lett. 1992 Aug 17;142(2):128-30
- Hauser RA, Lyons KE, McClain T, Carter S, Perlumtter D. Randomized, double blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord, 2009 May 15; 24(7):979-83
- Ferreira B, Mendes F, Osorio N, Caseiro A, Gabriel A, Valado A. Glutathione in multiple sclerosis. Br J Biomed Sci. 2013;70(2):75-9